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Abstract 
   A family with familial amyloid polyneuropathy (FAP) due to a transthyretin (TTR) 
Leu58Arg mutation was investigated clinicopathologically.  The proband presented with 
sensori-motor-autonomic polyneuropathy, and autopsy demonstrated massive amyloid 
deposition in the peripheral nerves and heart.  However, the mother was characterized by 
carpal tunnel syndrome and ocular vitreous opacities.  Thus, there was considerable 
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1. Introduction 
   Familial amyloid polyneuropathy (FAP) is a disorder with autosomal dominant 
inheritance caused by a mutant transthyretin.  The clinical features include neurologic and 
non-neurologic manifestations such as sensorimotor polyneuropathy, autonomic 
dysfunction, carpal tunnel syndrome (CTS), cardiomyopathy, renal dysfunction, 
gastrointestinal dysfunction, endocrine dysfunction, vitreous opacity, and glaucoma.   
Major foci of FAP are located in Japan, Portugal, and Sweden [1].  In those areas, a TTR 
Val30Met mutation is most common cause [1]; patients with the Val30Met mutation 
usually present with sensory dominant polyneuropathy, autonomic failure, rhythm and 
conduction disturbances of heart, and renal failure.  Recently, more than 100 single or 
double mutations and a deletion in the TTR gene have been reported to be associated with 
FAP [1].   
   In 1991, a new mutation causing TTR, Leu58Arg, was reported in a family in 
Kanazawa, Japan [2].  However, clinical and pathologic features associated with this 
mutation have not been studied.  There have not been any reports of other FAP families 
with the Leu58Arg mutation.  We here describe, for the first time, clinicopathologic 
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features of the Japanese FAP kindred with a Leu58Arg TTR mutation. 
 
2. Case reports 
   Patient 1 (V-I).  A 35-year-old man developed left leg weakness without sensory 
disturbance, and muscle weakness of the both legs slowly progressed.  He originated 
from Kanazawa, Ishikawa prefecture, Japan.   His family history through six generations 
demonstrated two affected and four presumably affected members with autosomal 
dominant inheritance (Fig. 1).  At age 37, neurologic examination demonstrated muscular 
atrophy and weakness in the distal extremities, dysesthesia in a glove and stocking 
distribution, and reduced deep tendon reflexes.  He also had orthostatic hypotension and 
impotence.  He had no symptom related to the central nervous system.  Urine analysis 
was normal, and echocardiogram showed mild thickening of the ventricular wall with 
normal wall motion.  Nerve conduction studies demonstrated a decrease in the amplitude 
of complex motor action potentials (CMAP) with decreased motor conduction velocities in 
the median and ulnar nerves.  Furthermore, CMAP was not evoked in the tibial or 
peroneal nerves.  Sensory nerve action potentials could not be elicited in the median, 
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ulnar or sural nerves.  EMG showed chronic denervation in the flexor carpi ulnaris and 
active denervation in the rectus femoris.  Sural nerve biopsy demonstrated marked loss of 
myelinated and unmyelinated fibers with slight amyloid deposition.  Sequencing analysis 
of the TTR gene following the single-strand conformation polymorphism (SSCP) analysis 
[2] disclosed a point mutation (CTC→CGC) at codon 58 changing leucine to arginine 
(Leu58Arg).   
   Thereafter, both the polyneuropathic and autonomic symptoms slowly progressed.  
He developed orthostatic syncope at age 42.  At age 43, the patient suddenly developed 
cardiopulmonary arrest, and died of pneumonia three weeks after.  The total duration of 
his illness was 9 years.  Autopsy was performed 2.5 hours after death.     
   Histopathological and immunohistochemical studies of the autopsied tissues 
demonstrated deposition of TTR-positive amyloid in systemic organs and tissues in 
various degrees (Table 1, Fig. 2).  The heart weighed 550 g, showing cardiomegaly with 
massive amyloid deposition in the endo- and myocardium (Fig. 2A). 
   Prominent amyloid deposition was found in the peripheral nervous system including 
the sciatic nerves (Fig. 2B).  In the central nervous system, massive amyloid deposition 
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was observed in the dura mater (Fig. 2F), in addition to mild amyloid deposition in the 
leptomeningeal vessels, subpial brain parenchyma (Fig. 2G), and choroid plexus.  
Besides the amyloid deposition, acute ischemic changes in the brain and purulent 
bronchopneumonia were observed. 
 
Patient 2 (IV-2).  The patient was the mother of Patient 1.  She complained of muscle 
weakness and dysesthesia in the right thumb at age 47.  Two month later, she also 
developed muscle weakness and dysesthesia in the left thumb.  She was diagnosed as 
having bilateral CTS.  She received local injection of corticosteroid and surgical 
treatment for the CTS.  Thereafter, however, her symptoms gradually progressed.  At 
age 53, she developed visual disturbance due to the vitreous opacities.  Neurological 
examination at age 62 demonstrated complete blindness in the right eye, blurred vision in 
the left eye, and reduced sense of touch, pain, and temperature and weakness of the hands 
due to the CTS.  The TTR Leu58Arg mutation was also detected [2].   
 
3. Discussion 
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   Our clinicopathologic investigation of a family with a TTR Leu58Arg mutation 
demonstrated considerable phenotypic difference between the two affected family 
members despite the identical TTR genotype.  Patient 1 was characterized by 
sensori-motor and autonomic polyneuropathy with motor involvement as an initial 
symptom and cardiac amyloidosis in the late stage, whereas Patient 2, the mother of 
Patient 1, presented with later onset and slower progression of CTS and vitreous opacities. 
   A variety of clinicopathologic phenotypes have been reported in association with a 
variety of TTR mutations.  CTS is the main feature of the disorder that was formerly 
called FAP type II, Rukavina [3] or Maryland type [4].  Maryland type FAP was reported 
to be related to a TTR Leu58His mutation [5-7].  Interestingly, this mutation is at the 
same site as the mutation found in our patients, but differed in the substituted amino acid.  
In addition to CTS, the clinical features of FAP with the TTR Leu58His mutation include 
progressive sensori-motor polyneuropathy, and cardiomyopathy or nephropathy in the 
advanced stage of the disease or at autopsy [4].  Onset with CTS and slowly progressive 
course in our Patient 2 with the Leu58Arg mutation resembled the features of FAP with the 
Leu58His mutation.  However, vitreous opacities as found in our Patient 2 are rare, and 
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polyneuropathy with initial motor involvement as found in our Patient 1 has not been 
previously reported in FAP with the Leu58His mutation [4-8].  It is reported that different 
TTR mutants are associated with differences in the efficiency of the endoplasmic 
machinery that targets destabilized mutant proteins for degradation and the enhanced 
tendency of these variants to aggregate if secreted, which may lead to different tissue 
selective amyloid diseases [9].  The phenotypic difference of FAP between the Leu58His 
and Leu58Arg mutations suggest differences in the secretion efficiency or aggregation 
characteristics of the TTR variants, despite the same mutation site, as the difference is 
found between TTR Val30Met and Val30Gly mutations [9]. 
   Different phenotypes between the affected family members despite the identical TTR 
genotype in this family would indicate that factors other than the mutant TTR influence the 
pathogenesis of FAP due to the Leu58Arg mutation, as suggested in FAP due to other 
mutations [10].  These factors would include environmental as well as the other genetic 
components, requiring further study.  
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Lung (vascular wall) +
Liver (vascular wall) +
kidney (glomeruli and vascular wall) +
Stomach (mucosa and submucosa) ++
Small intestine (mucosa and submucosa) +
Colon (mucosa and submucosa) +






Subpial brain parenchyma +
Choroid plexas +
-, absent;  +, slight deposition;  ++, moderate deposition; +++, marked deposition
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Figure legends 
Figure 1. The pedigree of the family.  An arrow (V-I) indicates the proband (Patient 1).  
Filled symbols indicate examined FAP patients, and crosshatched symbols indicate 
unexamined patients suspected of FAP. 
Figure 2. Pathologic findings in Patient 1.  Amyloid deposits, positive for Congo red (A, 
B, F, G) with green birefringence under polarized light (C, H), were seen in the 
myocardium (A), sciatic nerve (B-E), dura mater of the sagittal sinus (F), and subpial 
region of the brain (arrow heads) (G, H).  The amyloid deposits are immunostained with 
an antibody to TTR (D), but not with an antibody to AA protein (E) or immunoglobulin 
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